A Bright Future for TGTX: Ublituximab’s Potential in MS Treatment

Photo of author
Written By Faith Boluwatife

In the twisted history of TGTX, the primary focus was always on the development of anti-cancer therapies, which included the oral PI3K inhibitor and its combination with the anti-CD20 monoclonal antibody ublituximab.

The program of ublituximab development for multiple sclerosis (MS) seemed to be a safe plan B that could yield in between a best-in-class follow-on drug and something next to a patented biosimilar.

As the years passed, cancer programs have been cleared, ublituximab has been approved by the FDA for the treatment of MS, and TGTX has become a single-drug MS-focused company.

Consistent Sales Growth and Financial Outlook


TGTX was able to demonstrate consistent sales growth of ublituximab. The company ended 2023 with $89 million in revenue and, in the first quarter of 2024, raised its revenue target to $270-$290 million for 2024.

Despite generating negative net cash flow due to new R&D programs (subcutaneous (SC) formulation of ublituximab and new allogeneic cell therapy for autoimmune disorders), it is anticipated that the current cash position (~$210 million) and positive cash flow from the ublituximab business will fund all operations to cash flow positivity.

Ublituximab in the MS Treatment Context

MS is an autoimmune disease of the brain, driven by immune cells (leukocytes) that destroy the neuronal sheath. Relapsing-remitting MS is the most prevalent phenotype, characterized by relapses and progressive neurological disability.

Disease-modifying therapies (DMTs) aim to prevent relapses and delay disability progression. Monoclonal antibodies (mAbs) are the most effective DMTs, with the FDA approving five for MS treatment: natalizumab, alemtuzumab, ocrelizumab, ofatumumab, and ublituximab.

Ublituximab, an anti-CD20 mAb, depletes B-cells (key pathogenic leukocytes in MS) by binding to their CD20 receptor. Compared to other anti-CD20 mAbs, ublituximab boasts a small competitive edge, including the lowest reported relapse rate, a short infusion time, and lower pricing.

These advantages may provide up to 30% of the market share. Traditional MS treatment approaches are shifting towards early proactive treatment with anti-CD20 mAbs, reducing non-drug-related healthcare costs and increasing the market share for these therapies.

MS Epidemiology

The prevalence of MS is approximately 370 per 100,000 people in the US, corresponding to 900,000 individuals. There are over 1 million people living with MS in Europe and 2.9 million worldwide. These numbers are rising due to improved diagnosis, treatment, and population growth.

Approximately 60% of diagnosed MS patients are treated with DMTs, narrowing the treatable patient population to ~460,000 in the US.

Market of Anti-CD20 mAbs for MS

Anti-CD20 is the only growing mAb class in MS, with combined sales of over $9 billion in 2023. About 40% of DMT-treated patients in the US use anti-CD20 mAbs. Ublituximab has entered a large and growing pharmaceutical market niche, competing with ocrelizumab and ofatumumab.

Future Competition for Ublituximab

The major threats to ublituximab include the entry of ocrelizumab biosimilars, subcutaneous (SC) forms of anti-CD20, and oral BTK inhibitors.

  1. Biosimilars: Ocrelizumab biosimilars are expected to enter the market by 2029-2030, potentially inducing a 30% drug price decline within three years and reducing the volume sales of the originator by 60-80%.
  2. SC vs. IV Administration Route: Patients prefer self-injectable SC drugs to intravenous infusions (IV). SC formulations will play a significant role in MS treatment, with SC anti-CD20 drugs having longer IP protection. TGTX’s move towards SC development is a necessity, albeit a bit late.
  3. BTK Inhibitors: These new treatments may overcome the limitations of anti-CD20 mAbs by targeting B-cells in the brain. However, development has been slow due to liver toxicity concerns and recent phase 3 trial failures. Given the high uncertainty, BTK inhibitors are not considered immediate competition.

Ublituximab NPV and Acquisition Prospects

Using a conservative patient-based model and a discounted cash flow model, the potential NPV of ublituximab is estimated at $2.9 billion at a discount rate of 12%. If TGTX fails to launch the SC formulation and loses biosimilar competition, NPV may decrease to ~$1.9 billion.

Including ex-US royalties, NPV could range between modest 15% and rosy 50% value, leading to an NPV surface stretching across discount rates and ex-US inflows.

Price Prospects and Conclusion


TGTX’s share price fluctuates at the low end of a justifiable fundamental value range. Despite uncertainties around peak sales and takeover potential, TGTX’s consistent sales growth and strategic moves suggest a bright future.

While a grim scenario involves disappointing sales and R&D failures, a bright future with growing sales and successful SC development seems more likely.

Clinical success of BTK inhibitors could limit acquisition prospects, but TGTX remains an intriguing investment target with significant potential for growth and acquisition.


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.